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Background: Upper and lower airways diseases share in part their pathogenic mechanisms and frequently occur
simultaneously as “United Airway Disease.” Local treatment with nebulizers delivers anti-symptomatic drugs in either
the upper or the lower airways, according to the particle size generated by the nebulizer. To our knowledge, no
nebulizer combines both application ways.
The aim of this study is to test the efficacy and usability of a new nebulizer (OMRON A3 complete), generating aerosols
with particles diameters of 2-4.5 μm, 4.5-7.5 μm or >7.5 μm, according to the user’s choice.
Methods: Seventy-seven patients between 5 and 17 years of age with a diagnosis of rhinitis or asthma were
examined. Oxymetazoline or Salbutamol were prescribed according to best clinical practice guidelines. Both drugs
were administered through the OMRON A3 Complete nebulizer, with a particle dimension of >7.5 μm to treat nasal
obstruction and 2-4.5 μm for bronchial obstruction. The efficacy of treatment was assessed by total nasal inspiratory
airflow and FEV-1, Tiffeneau index (FEV1/FVC) and MMEF 25/75 respectively, 10 min before and after treatment.
Symptom improvement and usability were measured by patients’ and doctors’ questionnaires.
Results: Overall, 77 patients seeking care for acute respiratory symptoms were assigned to the upper (n = 39) or lower
(n = 38) airways disease group. For symptoms of the upper airways, 92% (95% CI, 77-97%) of the patients reported
subjective improvement, while 87% (95% CI, 73-94%) did so for the lower airways. The average total nasal inspiratory
airflow improved significantly (p = 0.030) among the patients with upper airways symptoms, from 275 ml/s (95% CI,
207-342 ml/s) to 359 ml/s (95% CI, 300-419 ml/s) after Oxymetazoline administration. All selected lung function
parameters (FEV1, Tiffeneau Index and MMEF25-75) significantly improved among the patients with lower airways
symptoms after inhalation of Salbutamol (p < 0.001). The nebulizer was assessed as “easy to use” by over 95% of
participants in both groups.
Conclusions: The OMRON A3 efficiently delivers anti-symptomatic drugs in both upper and lower airways in a user-
friendly way. This device may be useful to facilitate adherence to a complete treatment of respiratory symptoms in
patients with symptoms of the so-called United Airway Disease.
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Acute and chronic respiratory diseases in childhood are
among the first causes of consultation in pediatrics and
cause an enormous health and economic burden [1].
Upper (e.g. rhinitis, sinusitis) and lower (e.g. bronchitis,
asthma) airways diseases share in part their pathogenic
mechanisms and frequently occur simultaneously in the
same patient [2–4]. Comorbidity of upper and lower
airways has been also defined as “United Airway
Disease” (UAD) [5].
To minimize systemic side effects, first-line treatment
of airways inflammation is frequently based on local,
rather than systemic drugs. Local treatments include
corticosteroids and β2-agonists for the lower airways, as
well as corticosteroids, nasal anticholinergics and decon-
gestants for the upper airways [2, 3]. Drugs can be
administered with metered dose inhalers (MDI), nebu-
lizers, or other devices [6]. The use of MDI is feasible
but requires education, adherence and compliance of
the patient, while nebulizers are suitable at any age as
they do not require special skill in the inhalation
technique [7].
Nebulizers are generally divided into two categories,
according to the aerosol particle size they produce, i.e.
3-5 μm or 7.5-10 μm to treat either the lower or the
upper airways, respectively. Consequently, UAD patients
needing local therapy for both upper and lower airways
cannot receive their drugs with the same nebulizer.
The primary aim of this study is to test the efficacy of
a new nebulizer (OMRON A3 complete) that can be
switched to generate aerosols with different particle
diameters: 2-4.5 μm, 4.5-7.5 μm or >7.5 μm. The
secondary aim of the study is to evaluate whether the
use of this new nebulizer is easy and well accepted by
patients. To this end, we examined the efficacy and
usability of A3C in school children affected by acute ex-
acerbation of asthma or rhinitis. We also assessed the
subjective patients’ and doctors’ evaluation of symptoms
improvement, acceptability, easiness, and comfort of the
use of this new device.
Methods
Study population and design
The study population consisted of 77 patients between 5
and 17 years of age seeking care for rhinitis or asthma
exacerbations in the Pediatric Outpatient Clinic of the
Charité Universitätsmedizin Berlin or in one of its refer-
ring practices. The children were eligible for the upper
airways study if they had: 1) a diagnosis of rhinitis with
no contraindications to the use of local alpha adrenergic
drugs; 2) a clear nasal blockage based on clinical assess-
ment; 3) no remarkable anatomical reasons explaining
nasal obstruction; 4) no intake of beta-blocker drugs. A
24-hourperiod free of alpha-adrenergic drugs was alsorequired before testing. The children were eligible for
the lower airways study if they had: 1) a diagnosis of asthma
with no contraindications to the use of beta-2 adrenergic
drugs; 2) clinically assessed bronchial obstruction; 3) no re-
markable anatomical reasons explaining bronchial obstruc-
tion or other severe chronic lung diseases; 4) no intake of
beta-blocker drugs. A 12-h period free of long- (LABA) or
short-acting β-adrenergic agonists was also required before
testing. The study was approved by the local ethic commit-
tee. Participants and parents or legal tutors provided in-
formed written consent at the time of enrollment.
The nebulizer
Drugs were administered through OMRON A3
Complete nebulizer (OMRON, Kyoto, Japan) (Fig. 1).
This device produces aerosolized particles with dif-
ferent granulometric characteristics, whose dimen-
sions are changed by switching a “Nebulization
Control Ring” (NCR). The NCR in position 1, 2, or 3
produces particles of >7.5 μm, 4.5-7.5 μm or 2-
4.5 μm, respectively. In the present study, position 1
was selected to treat nasal obstruction and position
3 was used to treat bronchial obstruction. Further
information on the A3C nebulizer can be found at




Children with nasal obstruction were treated with
120 μg Oxymetazoline (6 drops of a solution at
0.05%) + 2.5 ml NaCl 0.9% administered for 5 to 7 min
with the A3C nebulizer (NCR in position 1). Children
with bronchial obstruction were treated with 1.25 mg
Salbutamol (5 drops of a solution at 5 mg/ml) + 2.5 ml
NaCl 0.9% administered for 8 to 10 min with the A3C
nebulizer (NCR in position 3).
Endpoints
The efficacy of the treatment with the A3C was mea-
sured at the individual level with questionnaires on the
patients’ and doctors’ opinion on symptoms improve-
ment. The efficacy of the drug delivery to the upper
airways was defined at population level by the increase
of the average total nasal inspiratory airflow (V’na) after
administration of Oxymetazoline with the A3C (see
below for details). V’na was measured according to
standard procedures [8] with Rhinomanometry (ZAN
100, N-spire Health, Germany) 10 min before and after
the treatment with Oxymetazoline. Participants were
asked to blow their nose before starting the assessment
and to breath normally with the mouth closed during
the measurement. Subjects were invited to introduce in
the nostrils the two plastic olives attached to flow and
Fig. 1 Omron A3C nebulizer Instruction Manual
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was evaluated separately [9].
The efficacy of drug delivery to the lower airways was
defined at population level by the increase of FEV-1,
Tiffeneau Index (FEV1/FVC) and Maximal Midexpiratory
Flow (MMEF 25/75) after administration of Salbutamol
with the A3C. These parameters were measured with a
Spirometer (ZAN 100, N-spire Health, Germany) 15 min
before and after the treatment with Salbutamol. The
doctors’ and patients’ opinions on the acceptability,
easiness, and comfort of the use of the A3C were assessed
through questionnaires. Patients were also asked to
estimate their satisfaction of the use of the nebulizer
through a Visual Analogue Scale (VAS).
Statistical analysis
Data were summarized as numbers (n) and frequencies
(%) if they were categorical and as mean and standarddeviation (SD) if quantitative. To assess the normal dis-
tribution of quantitative data, the Shapiro–Wilk test was
applied. A paired-samples t-test, when conditions were
respected or Wilcoxon signed-rank test were performed
to show differences in time within each group of
patients. A p-value <0.05 was considered statistically
significant. Statistical analyses were performed with R
statistical software (R Core Team, 2014), version 3.2.3.
Results
Characteristics of the study population
Overall 87 patients seeking care for acute respiratory
symptoms were examined, of which 77 met the inclusion
criteria to be assigned to the upper (n = 39) or to the
lower (n = 38) airways disease group (Table 1). Allergic
rhinitis (33/39; 85%) and allergic asthma (31/38; 82%)
were the most frequently diagnosed diseases in the
group with upper and lower airways disease, respectively.
Table 1 Characteristics of the study population and of the current
disease exacerbation
rhinitis asthma
n = 39 n = 38
Male gender, n (%) 25 64 27 71
Age (yrs), mean (SD) 9 3.0 10 3.0
Height (cm), mean (SD) 139 17 143 18
Weight (kg), mean (SD) 37 18 39 16
Atopic diseases, n (%)
Allergic rhinitis 33 85 21 55
Allergic asthma 24 62 31 82
Etiology, n (%)a
Viral 24 62 11 29
Bacterial 1 3 1 3
Allergic 27 69 26 68
Other 4 10 8 21
Severity, n (%)
low 1 3 13 34
medium 31 79 16 42
high 4 10 7 18
very high 3 8 2 5
Duration, n (%)
1-3 days 4 10 21 55
4-7 days 12 31 6 16
7-15 days 11 28 8 21
> 15 days 12 31 3 8
Impaiment of sleeping, n (%) 18 46 13 34
Impairment of eating, n (%) 0 0 3 8
Data were summarized as numbers (n) and frequencies (%) if they were categorical
and or mean and standard deviation (SD) if quantitative
aMore than one etiology is possible in the same subject
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common triggers of the acute exacerbation to be treated.
The severity of symptoms to be treated was classified as
“moderate” by the patients in 79% and 42% of those
having upper or lower airways symptoms, respectively.
Symptoms were more frequently short lived (1-3 days)
in the group with lower airways disease than in that with
upper airways disease (55% vs 10%, p < 0.001), but the
latter suffered more frequently from sleep impairment
(46% vs 34%, p = 0.285) (Table 1).Efficacy
The percentage of patients reporting a subjective feel-
ing of clear symptoms improvement was 92% (95%
CI, 77-97%) and 87% (95% CI, 73-94%) in the upper
and lower airways disease groups, respectively (Fig. 2).
Doctors judged a clear improvement of symptoms in
90% (95% CI, 76-96%) and 97% (95% CI 87-100%) ofthe patients with upper and lower airways disease,
respectively (Fig. 2).
The average total nasal inspiratory airflow significantly
improved (p = 0.030) among the patients with upper
airways symptoms, from 275 ml/s (95% CI, 207-342 ml/s)
to 359 ml/s (95% CI, 300-419 ml/s) after Oxymetazoline
administration with the A3C nebulizer (Table 2). The
frequency distributions of V’na values measured before
and after nebulization were notably different. Particularly,
V’na values evaluated after nebulization were distributed
towards higher values, with a peak in interval between 51
and 75 V’na (%). Moreover, the mean differences resulted
statistically significant (44% vs 61%, p = 0.010) (Fig. 3a).
All the selected lung function parameters (FEV1,
Tiffeneau Index and MMEF25-75) significantly im-
proved among the patients with lower airways symptoms
after inhalation of Salbutamol (Table 2). Similarly,
MMEF 25/75 values measured after nebulization
revealed a tendency towards higher values, with a peak
in the interval between 61 and 80 MMEF 25/75 (%).The
mean pre-post nebulization differences were statistically
significant (51% vs 77%, p < 0.001) (Fig. 3b).
Usability
Only 1/39 patients with upper airway disease (3%) and
2/38 patients with lower airway disease (5%) reported a
previous use of the A3C nebulizer. The nebulizer was
assessed as “easy to use” by 97% of the participants in
both groups (Fig. 2a). 85% and over 92% of the partici-
pants with disease of the upper or lower airways,
respectively, expressed the wish to use the nebulizer
again. More than 85% of the patients affected by UAD
considered the possibility of using one single nebulizer
to treat their symptoms of both upper and lower airways
as useful. Overall, only seven patients evaluated the use
of the nebulizer as “uneasy” (Fig. 2a). Doctors did not in-
dicate any problem in the patients’ use of the device for
both groups and would have prescribed the use of the
nebulizer for over 90% of their patients again (Fig. 2b).
Discussion
What we found
We tested the efficacy and usability of a novel
nebulizer (A3 complete, OMRON, Kyoto, Japan) in
two groups of children with either upper or lower
airways disease. In both groups the nebulizer was
considered as “easy to use” by the patients. The suc-
cessful delivery of the anti-symptomatic drug (Oxyme-
tazoline or Salbutamol) was assessed at individual
level through the subjective opinion of the patients
and their doctor. At population level, the success of
drug delivery in the target tissue was measured by
the improvement of objective upper or lower airways
parameters, i.e. total inspiratory nasal airflow and
Fig. 2 Subjective evaluation (a) Subjective patient’s evaluation of the use of the A3C nebulizer in 39 rhinitic patients and in 38 asthmatic patients.
A response between 1 and 4 in a Visual Analogue Scale from 1 to 10 was considered as positive. b Doctor’s evaluation of the use of the A3C
nebulizer in 39 rhinitic patients and in 38 asthmatic patients
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MMEF 25/75) To our knowledge, this is the first ex-
ample of a nebulizer being able to effectively deliver
drugs to both the upper and lower airways; actually,
no nebulizer with this property has been mentioned





Total nasal inspiratory airflow (ml/s) 275
Asthmatic patients
FEV 1 (l) 1.59
Tiffeneau index (%) 78
MMEF 25-75 (l/s) 1.32
Quantitative data were summarized as mean and standard deviation (SD)
aA paired t-test, when condition were respected (Shapiro-Wilk test was used to asse
differences in time within each groupDrug deposition in upper/lower airways
The efficacy of drug delivery in the lower airways was
clearly detected at population level in terms of variation of
FEV-1. This increase was remarkably evident when the
Maximal Midexpiratory Flow (MMEF25-75) was taken
into account. This suggests a successful penetration andnitic patients and in 38 asthmatic patient after drug administration
post p-valuea
SD mean SD
216 359 188 0.030
0.63 1.90 0.80 <0.001
11.0 87 10.1 <0.001
0.50 2.01 0.85 <0.001
ss normality of data), or Wilcoxon signed-rank test was performed to show
Fig. 3 Objective evaluation of (a) quantitative improvement of the Total Nasal Inspiratory Airflow at population level and (b) quantitative improvement of
the Maximal Midexpiratory Flow at population level. a Smoothed frequency distribution of V’na values (expressed as percentage (%) of the expected value)
measured before (pre) and after (post) nebulization. b Smoothed frequency distribution of MMEF 25/75 values (considered as percentage (%) of the
expected values) measured before (pre) and after (post) nebulization
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segment of the airways, i.e. the medium-size and
smaller bronchi. Accordingly, this improvement was
also accompanied by a clear improvement of the
Tiffeneau Index. Most of the patients subjectively
reported improvement of their bronchial symptoms,
assessed both through specific questioning (87%) and
a visual analogue scale (89%). The efficacy of drug
delivery in the upper airways was detected at popula-
tion level by measuring the total nasal inspiratory
flow. This objective improvement suggests the effect-
ive penetration and deposition of the drug (Oxymeta-
zoline) in the upper airways. Accordingly, most
patients subjectively reported improvement of their
nasal symptoms.
Usability of the device for patients with UAD
The improvement of subjective and objective symptoms
reflects why patients and doctors consider the use of the
nebulizer successful. Interestingly, the patients withsymptoms in both upper and lower airways expressed
appreciation for the possibility of treating both affected
sites with a unique nebulizer. Additionally, the instru-
ment seemed to be user-friendly for most of the partici-
pating patients. In certain patients (e.g. pre-school
children, patients with difficult coordination or low
attention) the use of a single and easier device, which is
able to treat both the upper and lower airways, may be
preferable and facilitate adherence to a complete treat-
ment of the so-called “United Airways Disease” [11, 12].
Choosing the appropriate device for each patient
Although the use of the A3C has been shown to be
beneficial for patients with rhinitis and asthma, one
should consider that nebulizers generally are not the
most frequently used drug delivery devices in the treat-
ment of both pathologies [13]. In particular, the
European and German national guidelines for the
treatment of rhinitis and asthma suggest as first choice
the use of nasal drops/sprays and metered dose inhalers
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corticosteroids in the upper and lower airways, respect-
ively [14, 15].
One of the reasons for this recommendation is that
most nebulizers are relatively big, not easily carried in-
struments, requiring electric power [16]. This impedes
an outdoor use, e.g. during sports or at school [17],
which is an essential limiting factor with regard to the
treatment of acute disease exacerbations, especially in
asthma. Moreover, some nebulizers have a relatively high
degree of variability in their efficiency of drug delivery
over time [18].
Study limitations
We have to acknowledge some limitations of our study.
First, we did not compare the efficacy of A3C with that
of other nebulizers. Nevertheless, the very high efficacy
measured suggests non-inferiority to other nebulizers
already available on the European market in delivering
drugs to either upper or lower airways. Second, we mea-
sured the impact of therapy only in not-hospitalized
patients affected by milder forms of acute exacerbations
of respiratory diseases. We stress that our conclusions
cannot be automatically extrapolated, without further
studies, to more severe conditions, such as severe
asthma, cystic fibrosis or to use in unconscious patients.
Third, the subjective opinion of patients and doctors
and the objective measures of lung or nasal function
were based on one episodic treatment only, without
further follow-up assessments. A study evaluating the ef-
ficacy of the instrument on patients monitored long-
term would have been more informative.
Conclusions
In conclusion, this study has shown that the A3C
nebulizer efficiently delivers anti-symptomatic drugs
in both the upper and lower airways in a user-
friendly way. This device may be useful to facilitate
adherence to a complete treatment of respiratory
symptoms in patients with symptoms of both upper
and lower airways symptoms, i.e. the so-called United
Airways Disease.
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